» Articles » PMID: 33186461

Che-1/AATF-induced Transcriptionally Active Chromatin Promotes Cell Proliferation in Multiple Myeloma

Abstract

Multiple myeloma (MM) is a hematologic malignancy produced by a clonal expansion of plasma cells and characterized by abnormal production and secretion of monoclonal antibodies. This pathology exhibits an enormous heterogeneity resulting not only from genetic alterations but also from several epigenetic dysregulations. Here we provide evidence that Che-1/AATF (Che-1), an interactor of RNA polymerase II, promotes MM proliferation by affecting chromatin structure and sustaining global gene expression. We found that Che-1 depletion leads to a reduction of "active chromatin" by inducing a global decrease of histone acetylation. In this context, Che-1 directly interacts with histones and displaces histone deacetylase class I members from them. Strikingly, transgenic mice expressing human Che-1 in plasma cells develop MM with clinical features resembling those observed in the human disease. Finally, Che-1 downregulation decreases BRD4 chromatin accumulation to further sensitize MM cells to bromodomain and external domain inhibitors. These findings identify Che-1 as a promising target for MM therapy, alone or in combination with bromodomain and external domain inhibitors.

Citing Articles

Molecular insights unlocking therapeutic potential for multiple myeloma and bone disease management.

Bruno T, Catena V, Blandino G, Fanciulli M, Di Agostino S J Exp Clin Cancer Res. 2024; 43(1):322.

PMID: 39695699 PMC: 11653552. DOI: 10.1186/s13046-024-03248-9.


Che-1/miR-590-3p/TAZ axis sustains multiple myeloma disease.

Bruno T, Catena V, Corleone G, Cortile C, Cappelletto M, Bellei B Leukemia. 2024; 38(4):877-882.

PMID: 38368441 PMC: 10997508. DOI: 10.1038/s41375-024-02168-z.


The new world of RNA diagnostics and therapeutics.

Blandino G, Dinami R, Marcia M, Anastasiadou E, Ryan B, Palcau A J Exp Clin Cancer Res. 2023; 42(1):189.

PMID: 37507791 PMC: 10386627. DOI: 10.1186/s13046-023-02752-8.


The Oncogenic and Immunological Roles of Apoptosis Antagonistic Transcription Factors in Human Tumors: A Pan-Cancer Analysis.

Lu F, Wu J, Zou H, Yang X, Wu Y, Xu J Oxid Med Cell Longev. 2022; 2022:3355365.

PMID: 36275893 PMC: 9581705. DOI: 10.1155/2022/3355365.


Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.

Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A Nat Immunol. 2022; 23(9):1379-1392.

PMID: 36002648 PMC: 9477743. DOI: 10.1038/s41590-022-01290-3.


References
1.
Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W . c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1):68-79. PMC: 3471363. DOI: 10.1016/j.cell.2012.08.033. View

2.
Brien G, Valerio D, Armstrong S . Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell. 2016; 29(4):464-476. PMC: 4889129. DOI: 10.1016/j.ccell.2016.03.007. View

3.
Misund K, Keane N, Stein C, Asmann Y, Day G, Welsh S . MYC dysregulation in the progression of multiple myeloma. Leukemia. 2019; 34(1):322-326. PMC: 6923575. DOI: 10.1038/s41375-019-0543-4. View

4.
Loven J, Hoke H, Lin C, Lau A, Orlando D, Vakoc C . Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013; 153(2):320-34. PMC: 3760967. DOI: 10.1016/j.cell.2013.03.036. View

5.
Welcker D, Jain M, Khurshid S, Jokic M, Hohne M, Schmitt A . AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer. Oncogene. 2018; 37(11):1503-1518. DOI: 10.1038/s41388-017-0054-6. View